Mammary Cell News Volume 14.11 | Mar 24 2022

    By
    Justin.choi
    -
    0
    99







    2022-03-24 | MCN 14.11


    Mammary Cell News by STEMCELL Technologies
    Vol. 14.11 – 24 March, 2022
    TOP STORY

    Biomimetic Hydrogel Supports Initiation and Growth of Patient-Derived Breast Tumor Organoids

    Investigators proposed a nanofibrillar hydrogel for the initiation and growth of breast cancer patient-derived tumor organoids.
    [Nature Communications]

    Full Article
    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.
    PUBLICATIONSRanked by the impact factor of the journal

    GIT1 Protects against Breast Cancer Growth through Negative Regulation of Notch

    Researchers showed that increased expression levels of G protein-coupled receptor kinase-interacting protein 1 (GIT1) correlated with high relapse-free survival in estrogen receptor-negative breast cancer patients and that GIT1 mediated negative regulation of Notch.
    [Nature Communications]

    Full Article

    Procr Functions as a Signaling Receptor and Is Essential for the Maintenance and Self-Renewal of Mammary Stem Cells

    By conditional knockout in mammary stem cells, investigators demonstrated that protein C receptor (Procr) was essential for mammary gland development and homeostasis.
    [Cell Reports]

    Full ArticleGraphical Abstract

    GNG2 Acts as a Tumor Suppressor in Breast Cancer through Stimulating MRAS Signaling

    G-protein gamma subunit 2 (GNG2) over-expression could significantly block the cell cycle, inhibit proliferation, and promote apoptosis in breast cancer cells in vitro.
    [Cell Death & Disease]

    Full Article

    CircRBM33 Downregulation Inhibits Hypoxia-Induced Glycolysis and Promotes Apoptosis of Breast Cancer Cells via a MicroRNA-542-3p/HIF-1α Axis

    Breast cancer clinical tissue samples were collected to test differential expressions of circRBM33, miR-542-3p, and HIF-1α. MCF-7 cells were subjected to normoxia or hypoxia and transfected with plasmids that regulated CircRBM33, miR-542-3p, and HIF-1α expression levels.
    [Cell Death Discovery]

    Full Article

    Enzyme-Sensitive Nanoparticles, Smart TAT and Cetuximab Conjugated Immunoliposomes to Overcome Multidrug Resistance in Breast Cancer Cells

    The authors synthesized, purified, and verified modified sets of lipids conjugated with cell-penetrating TAT peptide, MMP2 enzyme-sensitive moiety, and cetuximab antibodies against the EGF receptor on HPLC, TLC, SEM, and DLS analyses.
    [Toxicology and Applied Pharmacology]

    AbstractGraphical Abstract

    Label-Free Enrichment of MCF7 Breast Cancer Cells from Leukocytes Using Continuous Flow Dielectrophoresis

    Scientists presented a continuous flow, antibody-free dielectrophoresis-based microfluidic device to concentrate MCF7 breast cancer cells, a well-established circulating tumor cell model, in the presence of leukocytes extracted from human blood samples.
    [Electrophoresis]

    Abstract

    Engineering Tumor Constructs to Study Matrix-Dependent Angiogenic Signaling of Breast Cancer Cells

    The authors reported the development of an in vitro 3D breast cancer model to investigate the effect of stromal crosslinking and consequent stiffening on the angiogenic activity of cancer cells.
    [Biotechnology Progress]

    Abstract

    Circ-TFF1 Promotes Breast Cancer Progression Through the MiR-129-2-3p/IRAK1 Axis

    Circular RNA-trefoil factor 1 (circ-TFF1) and interleukin-1 receptor-associated kinase 1 (IRAK1) were highly expressed in breast cancer tissues and cells. Silencing of circ-TFF1 reduced the proliferation, migration, invasion and tube formation, while increasing the apoptosis of MDA-MB-361 and SK-Br-3 cells.
    [Biochemical Genetics]

    Abstract
    Keep current with the latest in organoid research.
    REVIEWS

    Cracking the Homologous Recombination Deficiency Code: How to Identify Responders to PARP Inhibitors

    Poly (ADP ribose) polymerase (PARP) inhibitors have shown substantial efficacy in BRCA-mutated ovarian cancer for several years, and their indication has gradually been extended to other tumor locations such as breast, prostate and pancreas.
    [European Journal of Cancer]

    Abstract

    New Advances in Targeted Therapy of HER2-Negative Breast Cancer

    Investigators describe the potential targets that may be used for breast cancer treatment from the aspects of PI3K/AKT signaling pathway, DNA damage response, angiogenesis, the cell cycle, breast cancer stem cells, etc.
    [Frontiers in Oncology]

    Full Article
    INDUSTRY AND POLICY NEWS

    FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy

    AstraZeneca and Merck announced that LYNPARZA has been approved by the FDA for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer.
    [Merck & Co., Inc.]

    Press Release

    Research Institute of the McGill University Health Center Team Receives Discovery of the Year Award from Québec Science Magazine

    The 2021 Discovery of the Year went to the work of Jean-Jacques Lebrun and his team to unveil the genetic mechanisms at work in aggressive TNBC and the discovery of a promising targeted combination therapy.
    [McGill Reporter]

    Press Release
    FEATURED EVENT

    ESMO Breast Cancer

    May 3 – 5, 2022
    Berlin, Germany

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Chemotherapy Resistance

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Fellowship – Pharmacometabolomics

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Fellow – Breast Cancer Metastasis

    Case Western Reserve University – Cleveland, OH, United States

    Postdoctoral Training Fellow – Gene Function

    Institute of Cancer Research – London, England, United Kingdom

    Senior Scientific Officer – Functional Genomics

    Institute of Cancer Research – London, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter